Patients with pure somatotroph tumors have been reported to be significantly more likely to have abnormal glucose metabolism than those with tumors that synthesize prolactin, a finding that is independent of GH/IGF-1 levels or tumor invasiveness and that appears to be independent of IGF-1 normalization [26]. The gene discussed is PRL; the disease is neoplasm.